Lazard Asset Management
LGND icon

Lazard Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Lazard Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-435
Closed -$45K – 2429
2025
Q1 		$45K Sell
435
-224
-34% -$25.3K ﹤0.01% 2014
2024
Q4 		$70K Sell
659
-1,507
-70% -$170K ﹤0.01% 1909
2024
Q3 		$216K Hold
2,166
– – ﹤0.01% 1592
2024
Q2 		$181K Buy
2,166
+981
+83% +$78.1K ﹤0.01% 1591
2024
Q1 		$86K Hold
1,185
– – ﹤0.01% 1587
2023
Q4 		$84K Hold
1,185
– – ﹤0.01% 1728
2023
Q3 		$71K Buy
1,185
+641
+118% +$42.2K ﹤0.01% 1752
2023
Q2 		$39K Buy
+544
New +$40.8K ﹤0.01% 1908
2023
Q1 		– Sell
-7,269
Closed -$485K – 2441
2022
Q4 		$485K Sell
7,269
-4,383
-38% -$285K ﹤0.01% 1131
2022
Q3 		$625K Buy
11,652
+10,232
+721% +$601K ﹤0.01% 1064
2022
Q2 		$79K Hold
1,420
– – ﹤0.01% 1604
2022
Q1 		$99K Buy
1,420
+30
+2% +$2.18K ﹤0.01% 1405
2021
Q4 		$133K Buy
1,390
+104
+8% +$9.61K ﹤0.01% 1362
2021
Q3 		$111K Sell
1,286
-115
-8% -$8.89K ﹤0.01% 1391
2021
Q2 		$114K Buy
1,401
+16
+1% +$1.33K ﹤0.01% 1311
2021
Q1 		$131K Hold
1,385
– – ﹤0.01% 1163
2020
Q4 		$85K Buy
+1,385
New +$79K ﹤0.01% 1222
2019
Q4 		– Sell
-8,735
Closed -$542K – 1602
2019
Q3 		$542K Buy
8,735
+5,109
+141% +$321K ﹤0.01% 814
2019
Q2 		$258K Sell
3,626
-2,106
-37% -$155K ﹤0.01% 1000
2019
Q1 		$449K Buy
5,732
+4,063
+243% +$308K ﹤0.01% 932
2018
Q4 		$141K Buy
+1,669
New +$178K ﹤0.01% 889
2014
Q4 		– Sell
-29,583
Closed -$867K – 1151
2014
Q3 		$867K Buy
+29,583
New +$982K ﹤0.01% 696

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's LGND Position: Q2 2025 in Review

Lazard Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 435 shares — an estimated $45K sold.

Lazard Asset Management first reported a position in LGND in Q3 2014 and held it in 22 quarters. The position peaked at $867K in Q3 2014. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Lazard Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 435 Ligand Pharmaceuticals shares in Q2 2025, an estimated $45K.
  • Lazard Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 22 quarters.
  • Lazard Asset Management's Ligand Pharmaceuticals position peaked at $867K in Q3 2014.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.